Procedures for multiple sclerosis: plasma exchange, AHSCT, and preparation before treatment

MS is usually not treated by surgically removing a particular lesion. A proposed procedure may mean plasma exchange after a severe attack, autologous haematopoietic stem-cell transplantation after careful selection, or an intervention for a specific symptom. Establish the complete name and intended purpose before assessing its suitability.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Marked visual loss, weakness, or walking difficulty warrants clinical evaluation rather than a search for a commercial package. The team should determine whether there is a new inflammatory event, infection, or another urgent cause. Fluctuation in an old symptom does not automatically justify apheresis or transplantation. NICE relapse-management recommendations
MIST compared transplantation with continued DMT in selected relapsing-remitting MS. It supports disease-control benefit in that setting, but its treatment era and comparator options do not represent every alternative available in 2026. An adverse event absent from a study is not proof of zero personal risk. Original MIST randomized trial
Prepare attack and imaging records, previous DMT doses and dates, reasons for stopping, infection history, and important comorbidities. State whether the consultation is about plasma exchange, AHSCT, or symptom management. A request for the most advanced treatment does not identify the required service.

Quick answer

Full guide

A patient may also need surgery for an unrelated condition. That is different from operating to alter MS itself. The MS team should know what is planned, while the procedural team needs information about immune treatment, recent disease activity, and relevant functional problems.

Assess a serious new deficit before choosing a procedure

Marked visual loss, weakness, or walking difficulty warrants clinical evaluation rather than a search for a commercial package. The team should determine whether there is a new inflammatory event, infection, or another urgent cause. Fluctuation in an old symptom does not automatically justify apheresis or transplantation. NICE relapse-management recommendations

If recovery after corticosteroids is inadequate, provide the symptom onset, actual treatment dates and doses, and the course of recovery. The clinician must distinguish a persistent severe deficit from ongoing recovery or a diagnosis that needs reconsideration. “Not completely better after treatment” is insufficient by itself to select the next intervention.

Plasma exchange has a role in selected difficult acute attacks

Therapeutic plasma exchange, often abbreviated TPE or PLEX, removes and replaces part of the plasma through an extracorporeal circuit. It may be considered for selected severe inflammatory demyelinating attacks with inadequate steroid response. The early randomized sham-controlled trial studied severe acute deficits, not every chronic symptom experienced by people with MS. Original randomized plasma-exchange trial

The 2023 ASFA guidance categorizes therapeutic apheresis by clinical indication. Application still requires a defined acute problem, an assessment of previous treatment, and an outcome to monitor. Inclusion in a guideline does not justify routine blood cleansing for every patient. ASFA ninth-edition apheresis guidance

When the goal is recovery from one severe attack, longer-term disease control remains a separate decision afterward. Ask how improvement will be measured, when it will be reviewed, and whether maintenance therapy needs reassessment. A beneficial response does not guarantee freedom from future attacks.

Understand access and monitoring requirements

The team evaluates vascular access, circulation, relevant laboratory results, and medicines before exchange. Hypotension, allergic reactions, calcium-related symptoms, and access complications require monitoring. Exchange can also affect the levels of some medicines, so treatment timing may need coordination. Canadian Blood Services therapeutic-apheresis guidance

Ask how the access will be maintained and which symptoms to report during and after treatment. Tell staff promptly about new tingling around the mouth, marked dizziness, breathing difficulty, or other concerning symptoms. Medication changes should come from the team rather than from an online preparation list.

Number and spacing of sessions depend on the clinical situation, response, and safety. If the quotation covers only one exchange, clarify access, replacement fluid, investigations, observation, and possible extension. More sessions do not independently establish greater benefit.

Immunoadsorption is a distinct intervention

Some centres may discuss immunoadsorption. It handles plasma components differently and should not be treated as interchangeable merely because both procedures are described as purification. A 2025 original study compared immunological effects and identified a need to relate those differences more fully to clinical outcomes. Plasma exchange versus immunoadsorption study

A greater change in a laboratory marker does not automatically mean greater recovery of vision or walking. Ask why the proposed technique fits your circumstances, what experience supports its use, and what alternatives exist. Patients should not have to choose by the name of the equipment.

AHSCT addresses immune disease activity rather than directly replacing nerves

Autologous haematopoietic stem-cell transplantation uses the patient's own haematopoietic cells with immune treatment and haematopoietic recovery. The 2025 ECTRIMS and EBMT consensus supports assessment in carefully selected settings, including highly active disease inadequately controlled by appropriate DMT. It is not a routine first step for every newly diagnosed patient. 2025 AHSCT consensus

Selection combines inflammatory activity, previous high-efficacy treatment, disease course, function, and fitness for the procedure. Age, duration, and disability inform that assessment, but illustrative figures in an article should not be converted into universal eligibility thresholds.

A person with longstanding progression and little evident inflammatory activity should not assume transplantation will repair years of established injury. The expected modifiable problem and the uncertainty require particular care in progressive presentations. Ask which desired outcomes have evidence and which remain speculative.

Evaluate the research without extending it beyond its population

MIST compared transplantation with continued DMT in selected relapsing-remitting MS. It supports disease-control benefit in that setting, but its treatment era and comparator options do not represent every alternative available in 2026. An adverse event absent from a study is not proof of zero personal risk. Original MIST randomized trial

The BEAT-MS registry describes a comparison of AHSCT with best available therapy for treatment-resistant relapsing MS. A registration explains the question being studied; it does not establish that final results have been published or that a Chinese institution has an available place. Official BEAT-MS registration

If a service advertises a similarly named intervention, request its actual protocol, team, local basis for use, and method of reporting outcomes. Patient stories convey experience but cannot replace studies with defined participants and follow-up. Distinguish haematopoietic transplantation from other cell products and unverified nerve-repair packages.

Plan for a continuous process from collection to recovery

AHSCT generally involves assessment, cell mobilization and collection, conditioning, reinfusion, and care through blood-count and immune recovery. It is not a single cell infusion followed by the end of medical responsibility. EBMT and JACIE recommendations address the procedural framework, centre standards, and multidisciplinary coordination, with later MS-specific issues updated in the 2025 consensus. EBMT and JACIE transplantation practice recommendations

Neurology evaluates disease suitability; the transplant service assesses organ function and treatment tolerance. Infection, rehabilitation, and reproductive specialists may also be involved. Ask who manages each stage and what findings allow progression to the next one. A booking made through sales staff alone does not complete the medical assessment.

Admission and recovery estimates must allow for the individual course. Request a staged outline with reasons that could delay discharge, such as infection, blood-count recovery, or additional observation. Travel bookings should accommodate those possibilities rather than impose an unchangeable medical deadline.

Address reproductive and infection issues before conditioning

Both men and women should receive counselling about possible reproductive effects before treatment. Fertility preservation, contraception, and later assessment depend on the actual protocol and individual plans. Return or absence of menstrual periods alone does not fully establish fertility or contraceptive needs.

Discharge does not mark complete immune recovery. Vaccination history, infections, and treatment exposures need a proper handover; revaccination may be required after transplantation. Live-vaccine decisions require specialist review of recovery and applicable guidance. General MS vaccination recommendations likewise recognize treatment-related differences rather than one schedule for everyone. ECTRIMS and EAN vaccination consensus

Obtain a route for fever or suspected infection and identify where timely testing and examination are available. Delayed messages across time zones cannot manage every recovery-period problem. The responsible team should assess readiness to leave the treatment city.

Carry rehabilitation goals through the procedure

Recording function beforehand helps interpret subsequent change. After transplantation or treatment of a major attack, fatigue, deconditioning, spasticity, and self-care problems may still need attention. Activity should be adjusted to current ability with assistance or professional guidance where appropriate. MS exercise and activity recommendations

A better walking day does not prove cure, and persistent fatigue during recovery does not independently establish failure. The clinical review should combine disease activity, functional measures, and personal goals at an appropriate time.

Obtain a verifiable procedural plan in China

Prepare attack and imaging records, previous DMT doses and dates, reasons for stopping, infection history, and important comorbidities. State whether the consultation is about plasma exchange, AHSCT, or symptom management. A request for the most advanced treatment does not identify the required service.

If the proposed care is part of research, verify the study, registration, ethics and consent arrangements, and screening or randomization requirements. China's updated drug clinical-trial quality-management rules took effect in September 2026. Advertising or a registration number alone cannot replace the formal research process. Official 2026 China drug clinical-trial GCP announcement

Confirm which stages the estimate covers, how complications will be managed, and who provides care after departure. The home service must be able to continue the required follow-up. Before suitability has been established, a price describes an offered service; it does not show that the intervention is appropriate for the individual.